Literature DB >> 11934728

Nuclear factor-kappaB activation in alveolar macrophages requires IkappaB kinase-beta, but not nuclear factor-kappaB inducing kinase.

Matthew Conron1, Evangelos Andreakos, Panagiotis Pantelidis, Clive Smith, Huw L C Beynon, Roland M Dubois, Brian M J Foxwell.   

Abstract

Cytokine mediated activation of alveolar macrophages (AMs) is an important event in the pathogenesis of fibrosing alveolitis (FA). Through membrane-associated antigens, cytokines (e.g., tumor necrosis-factor-alpha and interleukin-1) are believed to activate a common kinase cascade that initiates the cytoplasmic degradation of IkappaB and nuclear translocation of "nuclear factor-kappaB" (NF-kappaB). In the nucleus, NF-kappaB promotes the transcription of genes encoding chemokines and cytokines involved in chronic inflammation. Preventing cytokine-mediated NF-kappaB activation is a potential strategy for attenuating the lung injury that occurs in FA. Previously, we have demonstrated that, unlike AMs from healthy volunteers, AMs from patients with inflammatory lung diseases express the coxsackie/adenovirus receptor and the alphav integrins required for adenovirus (Adv) infection. This property allows Adv-mediated transgene delivery to diseased, but not normal, AMs and analysis of molecular pathways involved in gene transcription. In this study, AMs were infected with Adv constructs expressing a defective beta subunit of IkappaB kinase (AdvIKKbetakd) and a defective NF-kappaB inducing kinase (AdvNIKkd) to investigate the contribution of these molecules to NF-kappaB activation. We observed that IKKbeta, but not NIK, was required for NF-kappaB activation. The results of this study identify IKKbeta, but not NIK, as a potential therapeutic target in diseases that involve NF-kappaB-dependent gene transcription.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934728     DOI: 10.1164/ajrccm.165.7.2107058

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

Review 1.  Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?

Authors:  M Feldmann; E Andreakos; C Smith; J Bondeson; S Yoshimura; S Kiriakidis; C Monaco; C Gasparini; S Sacre; A Lundberg; E Paleolog; N J Horwood; F M Brennan; B M J Foxwell
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

2.  Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-kappaB pathway.

Authors:  Gabriele Gunella; Claudio Bardelli; Angela Amoruso; Ilario Viano; Piero Balbo; Sandra Brunelleschi
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 3.  Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

Authors:  B Foxwell; E Andreakos; F Brennan; M Feldmann; C Smith; M Conron
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

4.  Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.

Authors:  E Andreakos; R O Williams; J Wales; B M Foxwell; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

5.  Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells.

Authors:  Matthew C Catley; Joanna E Chivers; Neil S Holden; Peter J Barnes; Robert Newton
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

6.  Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis.

Authors:  Claudia Monaco; Evangelos Andreakos; Serafim Kiriakidis; Claudia Mauri; Colin Bicknell; Brian Foxwell; Nicholas Cheshire; Ewa Paleolog; Marc Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-02       Impact factor: 11.205

7.  Effects of intratracheal administration of nuclear factor-kappaB decoy oligodeoxynucleotides on long-term cigarette smoke-induced lung inflammation and pathology in mice.

Authors:  Yu-Tao Li; Bei He; Yu-Zhu Wang; Jing Wang
Journal:  Respir Res       Date:  2009-08-25

Review 8.  Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease.

Authors:  Michael R Edwards; Nathan W Bartlett; Deborah Clarke; Mark Birrell; Maria Belvisi; Sebastian L Johnston
Journal:  Pharmacol Ther       Date:  2008-10-06       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.